TF and cancer: Tisotumab vedotin is a humanized anti-TF antibody conjugated to monomethyl auristatin E. It was selected from a panel of anti-TF antibodies due to its ability to inhibit TF:FVIIa mediated intracellular signaling, promote antibody-dependent cell-mediated cytotoxicity, and be rapidly internalized by cancer cells with only a minimal impact on coagulant potential [115].